Seer : JP Morgan Healthcare Conference 2022 Presentation

Seer Presentation

Seer

40th Annual J.P. Morgan Healthcare Conference

Omid Farokhzad, M.D.

CEO, Seer

January 10, 2022

© Seer, Inc. All rights reserved. All trademarks are the property of Seer Bio or their respective owners.

Safe Harbor Disclosures

Certain statements in this presentation and the accompanying oral commentary are forward-looking statements within the meaning of the federal securities laws. These statements relate to future events or Seer, Inc. (the "Company")'s future results and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "to," "target," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology.

All statements other than statements of historical fact could be deemed forward-looking. These forward-looking statements are subject to a number of risks, uncertainties

and assumptions, including, among other things: any expectations regarding the Company's projections of market opportunities; statements regarding the Company's business strategy, operations, results of operations, financial needs, and financial condition; statements regarding the Company's long-term expectations; statements that may suggest trends for the Company's business or industry, including expectations that may affect the unmet need and the size of the proteomics market and adjacent markets; statements about the Company's broad commercial release, the center of excellence program and consortium arrangement, statements about the Company's ability to successfully commercialize the Proteograph™ Product Suite, demand for the Proteograph Product Suite; the launch of any new or additional products, any expectations or statements regarding customer acquisition in domestic or global markets, including but not limited to Europe and Asia; statements regarding customer adoption of new technologies domestically and globally; the Company's ability to expand life sciences markets through the use of its technology; the discovery of new protein variants and novel biomarkers leading to therapeutic breakthroughs, the scope of protection the Company is able to successfully establish and maintain for intellectual property rights, including its Proteograph Product Suite; projections, assumptions, and estimates of the Company's future performance and the future performance of the markets in which it operates; the Company's expectations regarding its gross margins, and operating income and expenses; any statements of the plans, strategies, and objectives of management for future operations; any statements of expectation or belief regarding future events, opportunities to drive future growth, and potential markets or market size, or technology developments.​

While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors may cause actual results, performance, or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this presentation are made only as of the date hereof. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, are described more fully in the Company's filings with the Securities and Exchange Commission ("SEC") and other documents that the Company subsequently files with the SEC from time to time. The Company specifically disclaims any intention to update any forward-looking statements included in this presentation. If one or more of these statements is updated or corrected, investors and others should not conclude that additional updates or corrections will be made.

In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of the Company.

2	© Seer 2022

We imagine and pioneer new ways to

decode the secrets of the proteome

to improve human health

3	© Seer 2022

Seer is leading the proteomics revolution

Leading customers and collaborators

Lighthouse customers

Well designed customer experience

Best in class technology

Uniquely enabling technology

Data demonstrating impact

Creating new markets

Industry leading partners Geographically positioned

Leading team with multi-omics expertise

Culture of innovation Industry-leading talent

4	© Seer 2022

Full characterization of the proteome is essential

	Genome	Proteome
	Static indicator of risk	Dynamic indicator of status
Accessibility	High accessibility	High utility but low	Utility
of content but low utility	accessibility of content

10M+ human exomes and	~1B genetic	< 0.2% of genetic variants
1M+ genomes and counting	variants catalogued	fully characterized

5

Source: UniProt, PNAS, PLOS

© Seer 2022